ANGO

Financial Performance: AngioDynamics Inc reported a total revenue of $72 million for the third quarter, marking a 9% year-over-year growth, with significant contributions from its MedTech segment which grew by 22%. The company also improved its adjusted EPS loss to $0.08 per share from $0.16 in the previous year.

Product Growth and Challenges: The Auryon platform and mechanical thrombectomy products showed strong growth, while the NanoKnife segment faced challenges with lower-than-expected capital sales and complex reimbursement processes. The company anticipates continued growth and expansion in its product offerings moving forward.

U.S. Stock Market Performance: U.S. stocks rose with the Dow Jones gaining 150 points, while private businesses added 155,000 jobs in March, surpassing expectations.

Sector Movements and Commodities: Real estate shares saw a slight increase, but information technology shares fell; meanwhile, commodities like oil and gold experienced minor gains.

Financial Performance: AngioDynamics reported a third-quarter 2025 adjusted EPS of 3 cents, surpassing expectations for a loss, with sales reaching $72 million, a 9.2% increase year-over-year. The company also noted improved gross margins and a positive outlook for fiscal year 2025.

Future Guidance: The company anticipates net sales between $285 million to $288 million for fiscal year 2025, with adjusted EBITDA expected to rise to $4 to $5 million, reflecting an optimistic growth trajectory despite flat projections for Med Device sales.

U.S. Stock Market Overview: U.S. stocks declined, with the Dow Jones index dropping over 100 points, while several companies like Cognyte Software and AngioDynamics saw significant gains after reporting better-than-expected financial results.

Notable Stock Performances: Cognyte Software's shares surged 22.1% following a strong earnings report, and other companies such as Rocket Companies and Cytokinetics also experienced notable increases in their stock prices.

Earnings Reports: Major companies such as AngioDynamics, Franklin Covey, BlackBerry, Resources Connection, RH, and Cognyte Software are set to report earnings today, with expected stock movements indicated by options prices.

Market Insights: Investors can view the anticipated earnings moves for these companies, which vary in percentage, and are advised to conduct thorough research before engaging in options trading due to associated risks.

Financial Performance: AngioDynamics reported a Q3 Non-GAAP EPS of -$0.08, beating expectations, with revenue of $72 million reflecting a 9.1% year-over-year increase. The company also improved its adjusted EBITDA to $1.3 million from a loss of $3.6 million in the previous year.

Fiscal Year 2025 Guidance: The company raised its fiscal year 2025 net sales guidance to $285-$288 million and expects Med Tech net sales growth of 14%-16%. Additionally, it anticipates an adjusted EBITDA of $4.0-$5.0 million and an adjusted loss per share improvement to between $0.31 and $0.34.

Financial Results Announcement: AngioDynamics, Inc. will report its third quarter fiscal year 2025 financial results on April 2, 2025, followed by a conference call at 8:00 am ET to discuss the results.

Investor Event: The company will also host a virtual cardiovascular investor event on the same day at 9:00 am ET to provide insights into its cardiovascular technology portfolio and strategic vision.

U.S. Stock Market Trends: U.S. stock futures are down, with the Dow futures decreasing by about 0.1%, while several companies, including UiPath Inc., SentinelOne, and American Eagle Outfitters, reported significant drops in pre-market trading following disappointing earnings results.

UiPath Earnings Report: UiPath's shares fell 16.7% after reporting a fourth-quarter revenue miss and issuing first-quarter guidance below estimates, despite beating earnings per share expectations.

Company Presentation Announcement: AngioDynamics, Inc. will have a presentation at the Oppenheimer 35th Annual Healthcare MedTech and Services Virtual Conference on March 17, 2025, featuring CEO Jim Clemmer and CFO Stephen Trowbridge.

About AngioDynamics: The company specializes in medical technology aimed at improving blood flow, cancer treatment options, and overall patient quality of life, with its innovative devices utilized by physicians in growing healthcare markets.

Gilat Satellite Networks Ltd. and AngioDynamics, Inc. Ratings: Both companies received upgraded ratings based on Kenneth Fisher's investment strategy, with Gilat Satellite Networks increasing from 50% to 70% and AngioDynamics from 48% to 60%, indicating improved fundamentals and valuations.

Kenneth Fisher's Investment Philosophy: Fisher, known for popularizing the price/sales ratio in stock evaluation, emphasizes low P/S ratios, profit growth, free cash flow, and consistent margins as key criteria for identifying attractive investments.

Trial Overview: AngioDynamics has initiated the AMBITION BTK trial to evaluate the effectiveness of the Auryon Atherectomy System combined with standard balloon angioplasty for treating below-the-knee lesions in patients with critical limb ischemia, enrolling up to 200 subjects across multiple sites.

Significance of the Auryon System: The Auryon Atherectomy System employs advanced laser technology to treat various types of arterial occlusions, aiming to improve outcomes for patients suffering from severe peripheral artery disease, particularly as treatment options remain limited for below-the-knee lesions.

APEX-AV Trial Results: AngioDynamics published results from the APEX-AV trial, demonstrating that the AlphaVac System effectively reduces RV/LV ratio and clot burden in patients with acute intermediate-risk pulmonary embolism (PE), with a 35.5% reduction in clots and minimal adverse events.

FDA Clearance and Market Response: The AlphaVac F1885 System received FDA clearance for PE treatment in April 2024, following the enrollment of 122 patients across 25 U.S. sites; AngioDynamics' stock saw a slight increase after the announcement.

Q2 Earnings Report: AngioDynamics, Inc. reported a 9.2% increase in net sales to $73 million for Q2 of fiscal year 2025, driven by growth in its Med Tech segment, despite a GAAP net loss and slight decline in the Med Device segment.

Future Outlook: The company is optimistic about continued growth in its Med Tech sector, particularly with its NanoKnife System, and expects to achieve adjusted EBITDA positivity for the fiscal year while expanding its global presence.

U.S. Stock Market Performance: U.S. stocks traded slightly lower with the Dow Jones down 0.1%, while initial jobless claims fell to their lowest level in eleven months at 201,000, indicating a stronger labor market than expected.

Sector Movements and Global Markets: Materials shares rose by 0.1%, but utilities dropped by 1%. European and Asian markets also experienced declines, with notable drops in indices like Germany's DAX and Japan's Nikkei 225.

U.S. Stock Market Overview: U.S. stocks declined with the Dow Jones falling over 150 points, while several companies like AAR Corp., Sana Biotechnology, and AngioDynamics saw significant gains due to strong earnings reports or positive clinical trial results.

Notable Stock Performances: AAR Corp. shares rose 9.6% after beating earnings estimates; Sana Biotechnology surged 249% following promising diabetes trial results; and eBay's stock increased 11.5% after a partnership announcement with Meta for Facebook Marketplace integration.

Earnings Reports Today: Major companies such as Acuity Brands, AngioDynamics, and Franklin Covey are set to report earnings today, with expected stock movements indicated by options prices.

Implied Moves: The anticipated price changes for these companies range from +/- 4.72% to +/- 20.21%, with specific figures provided for those reporting before and after market close.

Earnings Performance: AngioDynamics Inc. reported a loss of $10.738 million for the second quarter, an improvement from last year's loss of $29.048 million, and exceeded analysts' expectations of a loss of $0.11 per share.

Revenue Decline: The company's revenue decreased by 7.9% to $72.845 million compared to $79.073 million in the same quarter last year.

Company Presentation Announcement: AngioDynamics, Inc. will have a presentation at the 43rd Annual J.P. Morgan Healthcare Conference on January 16, 2025, featuring CEO Jim Clemmer and CFO Stephen Trowbridge.

Company Overview: AngioDynamics is focused on medical technologies that restore blood flow, enhance cancer treatment options, and improve patient quality of life, with their innovations being utilized by physicians in growing healthcare markets.

Investor Event Announcement: AngioDynamics, Inc. will host a virtual investor event on January 8, 2025, at 9:30am ET, following their Fiscal 2025 Second Quarter Financial Results Conference Call at 8:00am ET.

NanoKnife System Overview: The event will focus on the NanoKnife System's irreversible electroporation technology, highlighting its potential as a standard treatment for prostate tumors and discussing its market opportunities and impact on patient care.

Market Update: Wall Street experienced a positive turn on Friday after a short downturn.

Upcoming Focus: Investors will be closely monitoring upcoming labor market reports for insights into the future direction of the U.S. economy and stock market.